Mar 31, 2025 8:30 am EDT LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
Mar 27, 2025 8:30 am EDT LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Mar 10, 2025 8:30 am EDT New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
Feb 25, 2025 8:30 am EST LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
Feb 13, 2025 10:35 am EST LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Feb 11, 2025 8:42 am EST LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Feb 10, 2025 5:00 pm EST LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Aug 26, 2024 8:30 am EDT First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
